Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
Cybin Inc. (HELP)
Company Research
Source: GlobeNewswire
Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as measured by MADRS score (mean difference: -7.35) versus placebo at two weeksAntidepressant treatment effects observed within one week and sustained for up to three months Findings reinforce the therapeutic potential of short-acting serotonergic agonists and inform Helus Pharma’s HLP004 development program, with Phase 2 topline data in generalized anxiety disorder (“GAD”) expected in Q1 2026 This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. BOSTON and TORONTO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (“NSAs”) for serious mental he
Show less
Read more
Impact Snapshot
Event Time:
HELP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HELP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HELP alerts
High impacting Cybin Inc. news events
Weekly update
A roundup of the hottest topics
HELP
News
- Cybin (HELP) had its price target raised by HC Wainwright from $55.00 to $95.00. They now have a "buy" rating on the stock.MarketBeat
- Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience [Seeking Alpha]Seeking Alpha
- Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory CommitteeGlobeNewswire
HELP
Earnings
- 2/13/26 - Miss
HELP
Sec Filings
- 2/24/26 - Form 6-K
- 2/18/26 - Form 6-K
- 2/17/26 - Form SCHEDULE
- HELP's page on the SEC website